Japan Exchange
07:56:59 10/05/2024 am IST
5-day change
1st Jan Change
1,413
JPY
+3.44%
-7.95%
-16.78%
Shin Nippon Biomedical Laboratories : Presentation materials for the First Three Months of the Fiscal Year Ending March 31, 2023
July 29, 2022 at 12:04 pm IST
The Fiscal Year Ending March 31, 2023
Presentation Materials on 1Q Financial Results
July 29, 2022
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
（ TSE PRIME: 2395）
Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.
1. Outline of 1Q Consolidated Financial Results
Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.
1
FY2023/3 1Q Consolidated Financial Results Highlights
Revenue
Operating Profit
Ordinary Profit
Ordinary Profit (excl. FX impact)
Profit Attributable to Owners of Parent
FY2023/3
１Q
Yoy
Results
40.4
+10.0
33.1%
7.1
+2.2
45.2%
27.7
+20.9
312.1%
10.8
+4.1
61.4%
19.4
+1.1
6.5%
Revenue
40.4
30.4
FY22/3 FY23/3
1Q 1Q
(100 million of yen)
Ordinary
Profit
27.7
6.7
FY22/3 FY23/3
1Q 1Q
Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.
2
Yoy Comparison of 1Q Consolidated Operating P/L
1Q FY2022/3
1Q FY2021/3
Yoy changes
Preclinical (Japan): Revenue +0.77 billion yen OP +0.22 billion yen
4.9
1Q FY22/3
CRO business
Translational
Medipolis
Operating
business (Power
profit
Other
Research
Generation &
total
Clinical
business
Preclinical
Hospitality)
(Japan)
9.0
0.0
-1.2
0.1
-0.8
7.1
6.6
0.0
-1.4
0.1
-0.4
4.9
+2.4
+0.0
+0.2
+0.0
-0.4
+2.2
+0.0
+0.2
+0.0
▲0.4
(100 million of yen)
+2.4
7.1
2.2
Preclinical
Clinical
Translational
Medipolis
Other
1Q FY23/3
(Power
(Japan)
Research
Generation &
Hospitality)
Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.
3
Yoy Comparison of 1Q Consolidated Ordinary P/L
1Q FY2023/3
1Q FY2022/3 Yoy changes
Medipolis
CRO business
Translational
Ordinary
business
Foreign
Other
profit
Clinical (incl.
Research
(Power
exchange
total
Preclinical
business
Generation &
gain and loss
PPD-SNBL)
Hospitality)
9.1
3.4
-1.2
0.1
16.8
-0.5
27.7
6.6
1.9
-1.4
0.1
0.0
-0.5
6.7
+2.5
+1.5
+0.2
+0.0
+16.8
-0.1
+20.9
(100 million of yen)
FY2022/6 results: 14.23 weaker yen ⇒ FX gain of 1.68 billion yen
FY2021/6 results: 0.1 stronger yen ⇒ FX gain of 0 million yen
▲0.1
Preclinical (Japan) business: Revenue +0.77 billion yen OP +0.22 billion yen
Equity in net income of
+16.8
PPD-SNBL +0.15 billion yen
affiliates, from SNBLChina: +20 million yen
6.7 +2.5
20.9
Clinical (incl.
Translational
FX gain
1Q FY22/3
Preclinical
Medipolis
Other
1Q FY23/3
PPD-SNBL)
Research
and loss
Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.
4
This is an excerpt of the original content. To continue reading it, access the original document here .
Attachments
Original Link
Original Document
Permalink
Disclaimer
Shin Nippon Biomedical Laboratories Ltd. published this content on 29 July 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 29 July 2022 06:33:03 UTC .
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024
02/02
CI
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval
18/01
MT
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024
07/11
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
02/23/02
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
02/23/02
CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting
15/23/15
CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.
08/23/08
CI
Jefferies Upgrades Shin Nippon Biomedical Laboratories to Buy From Hold, Adjusts Price Target to 2,800 Yen From 2,300 Yen
29/23/29
MT
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
08/23/08
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
08/23/08
CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023
08/23/08
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
08/23/08
CI
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 2,300 Yen From 3,800 Yen
18/23/18
MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals
18/23/18
MT
Sector Update: Health Care Stocks Higher Premarket Monday
17/23/17
MT
Bank Earnings in Focus as US Equity Futures Tread Water
17/23/17
MT
Top Premarket Gainers
17/23/17
MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical
17/23/17
MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.
17/23/17
CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
31/23/31
CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023
31/23/31
CI
Shin Nippon Biomedical Laboratories, Ltd. Announced Dividend for the Second Quarter of Fiscal Year Ending March 31, 2023, Commence Payments from November 30, 2022
31/22/31
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
31/22/31
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
31/22/31
CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Dividend on Retained Earnings, Effective November 30, 2022
31/22/31
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
More about the company
Last Close Price
1,366
JPY
Average target price
3,150
JPY
Spread / Average Target
+130.60%
Consensus
1st Jan change
Capi.
-16.78% 378M +23.37% 46.71B +48.83% 41.8B -0.94% 41.52B -5.86% 29.55B +11.29% 25.78B -20.92% 19.26B +3.20% 12.14B -2.67% 12.08B +30.23% 11.98B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
